Tirzepatide

Overview

Evidence tier: 5 — editorial framing of the peptide-page entity context.

Tirzepatide is the first commercially approved dual GIP/GLP-1 receptor agonist. Where semaglutide activates only the GLP-1 incretin pathway, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — and the addition of GIP signaling appears to translate into measurably superior weight-loss and metabolic effects. Eli Lilly's molecule was FDA-approved as Mounjaro for type 2 diabetes in May 2022, as Zepbound for chronic weight management in November 2023, and as Zepbound for obstructive sleep apnea in December 2024.

The dual mechanism produces unusually strong head-to-head data. SURMOUNT-5 (2025) compared tirzepatide and semaglutide directly in adults with obesity: 20.2% mean weight loss with tirzepatide vs 13.7% with semaglutide. SURPASS-2 had earlier shown tirzepatide superiority for HbA1c and weight in type 2 diabetes. By any reasonable measure, tirzepatide is the most effective peptide weight-loss drug currently approved.

How it works

Evidence tier: 2 — mechanism documented in published pharmacology literature.

GLP-1 receptor activation is the foundation — the same appetite suppression, glucose-dependent insulin enhancement, and slowed gastric emptying that drive semaglutide's effects. GIP receptor activation adds additional benefit through pathways that are still being characterized: more efficient nutrient partitioning, additional appetite-suppression signaling in the brain, and possibly direct effects on adipose tissue lipid metabolism.

Pharmacokinetically, tirzepatide has a 5-day half-life — slightly shorter than semaglutide's 7 days — but still well-suited to once-weekly dosing. The long half-life is achieved through a fatty-acid side chain that allows reversible albumin binding, the same engineering trick used in semaglutide.

Side effects, risks, and practical use

Evidence tier: 3 — clinical case-series + animal-model adverse-event data; magnitude varies by molecule.

Side-effect profile is similar to semaglutide but generally more pronounced — the GI symptoms (nausea, vomiting, diarrhea) tend to be more intense during titration. About 5–10% of patients discontinue due to GI intolerance. Same black-box warning for thyroid C-cell tumors based on rodent data; same contraindication in personal or family history of medullary thyroid carcinoma or MEN 2. Same risk of acute pancreatitis. Same dependence on continued use to maintain weight loss.

Practical considerations:

• Cost. Branded Zepbound is $1,000–1,300/month without insurance. Compounded versions exist in a legally contested zone. The forthcoming oral GIP/GLP-1 orforglipron (Foundayo) launched at $25/month in April 2026 and will rapidly reshape the market.
• Dosing. Standard weekly titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Not every patient needs the maximum; many achieve sufficient effect at 5–10 mg.
• Switching from semaglutide. Common in clinical practice when semaglutide-mediated weight loss plateaus. Re-titration is required.
• Discontinuation. Same weight-regain dynamic as semaglutide. Discontinuation is not "stopping a diet"; it is removing an appetite-suppressing drug, with the predictable physiology that follows.

Trial readouts that matter

Evidence tier: 2 — references summarized in the body; see Trial readouts section below for primary-source detail.

SURMOUNT-1 (Jastreboff 2022, NEJM, PMID 35658024) established 22.5% mean weight loss at the 15 mg dose over 72 weeks in adults with obesity but without type 2 diabetes — substantially higher than any prior monotherapy. SURMOUNT-5 (Aronne 2025, NEJM, PMID 40353578) is the head-to-head against semaglutide: tirzepatide produced 20.2% loss vs semaglutide's 13.7% over 72 weeks, with similar discontinuation rates. SURPASS-2 (Frias 2021, NEJM) established the HbA1c advantage in type 2 diabetes vs semaglutide 1 mg.

The December 2024 FDA approval of tirzepatide for obstructive sleep apnea (the SURMOUNT-OSA trials) was the first GLP-1-class approval for OSA, mediated by weight loss but with regulatory implications for insurance coverage. The cardiovascular outcomes program (SURPASS-CVOT) is the major outstanding readout — expected 2026-2027.

Where to go from here

Evidence tier: 5 — editorial framing of the peptide-page entity context.

For the broader Weight Loss pillar including the older AOD-9604 fragment peptides and the emerging oral GLP-1s, see the goal-based hub. For the head-to-head comparison with semaglutide, see /compare/semaglutide-vs-tirzepatide. For per-state legal and access considerations, see the legal status guide.

Related on Peptide Story

• Weight Loss pillar — GLP-1 / GIP class context
• Retatrutide vs Tirzepatide — comparison
• Semaglutide vs Tirzepatide — SURMOUNT-5

References

• Jastreboff A.M. et al. 2022. SURMOUNT-1: Tirzepatide Once Weekly for Treatment of Obesity. N Engl J Med.
• Aronne L.J. et al. 2025. SURMOUNT-5: Tirzepatide vs Semaglutide for Obesity. N Engl J Med.